Kidney Cancer

Our study demonstrated, downregulation of hsa-miR-200b-3p in ccRCC holds promise as a potential diagnostic biomarker and its identified target NDUFS1 as an independent prognostic biomarker for patients with ccRCC. These findings need to be validated in a large cohort of patients with RCC.

Our findings reveal an intrinsic SLFN11-dependent vulnerability in ccRCC that synergizes with alkylating agents to induce an acquired PARP-1 dependency, thereby sensitizing BRCA1/2-WT tumors to PARP inhibition. Therefore, this work uncovers a potential therapeutic strategy for targeting SLFN11-high kidney cancers.

These nanoparticles exhibited optimal physicochemical properties, efficiently restored FDX1 palmitoylation, rescued CD8+ T cell function, and synergized with PD-1 blockade in preclinical RCC models without inducing systemic toxicity. Our findings uncover the iron-ZDHHC12-FDX1 axis as a metabolic checkpoint of T cell immunity and demonstrate a nanotechnology-based strategy to overcome iron-driven immunosuppression, offering translational potential for patients with iron-overloaded RCC.

P=N/A, N=40000, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Initiation date: Jul 1992 --> Apr 2002

Postoperatively, the patient received chemotherapy with epirubicin combined with ifosfamide. Follow-up showed no significant evidence of metastasis or recurrence. This report aims to provide clinical reference regarding the imaging findings and diagnosis of this rare disease, primary renal synovial sarcoma.

Belzutifan led to radiographic improvement in pulmonary metastases and symptoms, while other lesions remained stable. This suggests its potential therapeutic use in TFE3-rearranged renal cell carcinoma.

The patient will be closely monitored for any signs of recurrence or metastasis. The associated prognosis for patients with nonmetastatic MESTKs exhibiting malignant transformation is unknown; however, strict follow-up is recommended due to the histological grade of malignancy and local invasion.

Together, these findings reveal that GPR132 signaling promotes ccRCC by sustaining mitochondrial integrity and elevating lactate import. The crosstalk between lactate and tumor cells is a metabolic vulnerability that can be disrupted by targeting GPR132, providing a potential treatment strategy for ccRCC.

TLN1 was markedly overexpressed in ccRCC tissues and cell lines, and its knockdown significantly reduced proliferation, migration, and colony formation in vitro, supporting a pro-tumorigenic function. This study uncovers platelet-related AS dysregulation in ccRCC and identifies TLN1 as a promising biomarker and therapeutic target, offering new insights into ccRCC pathogenesis and treatment strategies.

P=N/A, N=90, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Sep 2026

In 1 patient, suspicious lymph nodes at standard imaging without PET uptake were negative at final pathology. Our findings generate the hypothesis that CAIX-PET might yield crucial information on cancer aggressiveness and systemic staging with potential key diagnostic, therapeutic and prognostic implications for patients with high-risk renal cancer.

Casdatifan has shown promising clinical activity in the ARC-20 ccRCC platform study, both as monotherapy and in combination with the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib. Currently, casdatifan is being evaluated in a Phase 3 trial in combination with cabozantinib (NCT07011719) in patients with advanced ccRCC.